Search Within

Dana Elizabeth Rathkopf

  1. "Nursing"
Formats
  1. Meeting Abstract (14)
  2. Journal Article (8)
Groups
  1. Department of Medicine (22)
  2. Genitourinary Oncology Service (22)
  3. Nursing (22)
  4. Solid Tumor Oncology Division (22)
  5. Advanced Practice Providers (9)
  6. Hematologic Malignancies, Division of (9)

More Groups

People
  1. Howard Scher (13)
  2. Tracy Smart-Curley (11)
  3. Michael Morris (10)
  4. Susan Slovin (9)
  5. Gary Schwartz (7)
  6. Gabrielle Arauz (6)

More People

Years
  1. 2024 (1)
  2. 2021 (1)
  3. 2018 (2)
  4. 2017 (1)
  5. 2016 (2)
  6. 2012 (4)

More Years

Publications
  1. Journal of Clinical Oncology (13)
  2. Annals of Oncology (2)
  3. Cancer Chemotherapy and Pharmacology (2)
  4. Investigational New Drugs (2)
  5. British Journal of Cancer (1)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (13)
  2. Springer (4)
  3. American Association for Cancer Research (2)
  4. Oxford University Press (2)
  5. Nature Publishing Group (1)

Results (22)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)
    Journal Article

    Zhao, J. L.; Antonarakis, E. S.; Cheng, H. H.; George, D. J.; Aggarwal, R.; Riedel, E.; Sumiyoshi, T.; Schonhoft, J. D.; Anderson, A.; Mao, N.; more...
    British Journal of Cancer (2024)

    Fulltext@MSK | Save
  • A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Zhao, J. L.; Antonarakis, S.; Cheng, H.; George, D. J.; Aggarwal, R. R.; Abida, W.; Decker, B.; Smart-Curley, T.; Schonhoft, J.; Anderson, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • c15-160: Enzalutamide (ENZA) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1b Prostate Cancer Clinical Trials Consortium study
    Meeting Abstract

    Rathkopf, D. E.; Autio, K. A.; Antonarakis, E. S.; Cheng, H. H.; Arauz, G.; Slack, A.; Hullings, M.; Scher, H. I.; Feng, F. Y.; Knudsen, K. E.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer
    Journal Article

    Graham, L.; Banda, K.; Torres, A.; Carver, B. S.; Chen, Y.; Pisano, K.; Shelkey, G.; Curley, T.; Scher, H. I.; Lotan, T. L.; more...
    Investigational New Drugs (2018)

    Fulltext@MSK | Save
  • Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy
    Meeting Abstract

    Slovin, S. F.; Knudsen, K. E.; Halabi, S.; Carbone, E.; Fernandez, C.; Chen, Y.; Autio, K. A.; Rathkopf, D. E.; Kampel, L.; Morris, M. J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A Phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Slovin, S. F.; Autio, K. A.; Delacruz, A.; Shelkey, G.; Pisano, K.; Hullings, M.; DeNunzio, M.; Morris, M. J.; Scher, H. I.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A phase 1/2 study combining ipilimumab with abiraterone acetate plus prednisone in chemotherapy- and immunotherapy-naive patients with progressive metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Danila, D. C.; Kuzel, T.; Cetnar, J. P.; Rathkopf, D. E.; Morris, M. J.; Alumkal, J. J.; Butler, A.; Curley, T.; Hullings, M.; Buddle, J. R.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Rathkopf, D. E.; Shore, N.; Antonarakis, E. S.; Berry, W. R.; Alumkal, J. J.; Tutrone, R.; Saleh, M. N.; Redfern, C. H.; Hauke, R. J.; Liu, G.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Steinbrecher, J. E.; Arauz, G.; Curley, T.; Rix, P. J.; Maneval, E. C.; Chen, I.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Steinbrecher, J. E.; Arauz, G.; Rix, P. J.; Maneval, E. C.; Chen, I.; Fox, J. J.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save